Prevalence evolution of SARS-CoV-2 infection in the city of São Paulo, 2020–2021
DOI:
https://doi.org/10.11606/s1518-8787.2021055003970Keywords:
Adult, COVID-19, epidemiology, COVID-19 Serological Testing, Health SurveysAbstract
OBJECTIVE To estimate the evolution of the prevalence of SARS-CoV-2 virus infection among residents aged 18 years or over in the municipality of São Paulo. METHODS This is a population-based household survey conducted every 15 days, between June and September 2020, and January and February 2021. In total, the study comprised 11 phases. The presence of antibodies against SARS-CoV-2 was identified in venous blood using a lateral flow test, Wondfo Biotech. In the last phase, the researchers combined it with an immunoenzymatic test, Euroimmun. The participants also answered a semi-structured questionnaire on sociodemographic and economic factors, and on social distancing measures. Prevalence estimates and the 95% confidence interval were estimated according to regions, Human Development Index, sex, age group, ethnicity, education, income, and variables associated with risk or prevention of infection. To compare the frequencies among the categories of each variable, the chi-square test with Rao-Scott correction was used, considering a significance level of 5%. RESULTS In total, 23,397 individuals were interviewed and had their samples collected. The estimated prevalence of antibodies against SARS-CoV-2 ranged from 9.7% (95%CI: 7.9–11.8%) to 25.0% (95%CI: 21.7–28.7). The prevalence of individuals with antibodies against the virus was higher among black and brown people, people with lower schooling and income, and among residents of regions with lower Human Development Index. The lowest prevalences were associated with recommended measures of disease protection. The proportion of asymptomatic infection was 45.1%. CONCLUSION The estimated prevalence of the infection was lower than the cumulative incidence variation, except for the last phase of the study. The differences in prevalence estimates observed among subpopulations showed social inequality as a risk of infection. The lower prevalence observed among those who could follow prevention measures reinforce the need to maintain social distancing measures as a way to prevent SARS-CoV-2 infection.
References
World Health Organization. WHO Coronavirus disease (COVID-19) pandemic. Geneva (CH): WHO; 2020 [cited 2020 Nov 13]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019 [ Links ]
Ministério da Saúde (BR). Portaria Nº 188 de 3 de fevereiro de 2020. Declara Emergência em Saúde Pública de Importância Nacional (ESPIN) em decorrência da infecção humana pelo novo Coronavírus (2019-nCoV). Diário Oficial da União. 4 fev 2020; Seção 1:1. [ Links ]
Ministério da Saúde (BR). Portaria Nº 454 de 20 de março de 2020. Declara, em todo o território nacional, o estado de transmissão comunitária do coronavírus (COVID-19). Diário Oficial da União. 20 mar 2020; Seção 1:1. [ Links ]
Ministério da Saúde (BR). COVID 19 - Painel Coronavírus: atualização diária. Brasília, DF; 2021 [cited 2021 Mar 28]. Available from: https://covid.saude.gov.br/ [ Links ]
São Paulo. Decreto Municipal Nº 59.298 de 23 de março de 2020. Suspende o atendimento presencial ao público em estabelecimentos comerciais e de prestação de serviços. Diário Oficial da Cidade de São Paulo. 23 mar 2020; Seção 1:1. [ Links ]
São Paulo. Decreto Municipal nº 59.473 de 29 de maio de 2020. Estabelece, nos termos do Decreto Estadual nº 64.994, de 28 de maio de 2020, normas para o funcionamento de estabelecimentos de comércio e de serviços localizados na Cidade de São Paulo, dispondo sobre o procedimento, condições e diretrizes para a gradual retomada de atividades, em conformidade com as diretrizes do Governo Estadual; prorroga o prazo previsto no artigo 1º do Decreto Municipal nº 59.298, de 23 de março de 2020, que dispõe sobre o combate à pandemia de Coronavírus. Diário Oficial da Cidade de São Paulo. 29 maio 2020; Seção 1:1. [ Links ]
Ministério da Saúde (BR). DATASUS: Serviços [cited 2021 Mar 21]. Available from: http://www2.datasus.gov.br/DATASUS/index.php?area=02 [ Links ]
Kish L. Survey sampling. New York: John Wiley; 1965. [ Links ]
Castro R, Luz PM, Wakimoto MD, Veloso VG, Grinsztejn B, Perazzo H. COVID-19: a meta-analysis of diagnostic test accuracy of commercial assays registered in Brazil. Braz J Infect Dis. 2020;24(2):180-7. https://doi.org/10.1016/j.bjid.2020.04.003 [ Links ]
SARS-CoV-2 Antibody Test (Lateral Flow Method). Guangzhou (CN): Wondfo Biotech; 2021. Available from: https://www.bilcare.com/SARS-CoV-2%20Antibody%20Test%20(Lateral%20Flow%20Method).pdf [ Links ]
Pellanda LC, Wendland EMR, McBride AJA, Tovo-Rodrigues L, Ferreira MRA, Dellagostin AO, et al. Sensitivity and specificity of a rapid test for assessment of exposure to SARS-CoV-2 in a community-based setting in Brazil. medRxiv [Preprint]. 2020 [posted 2020 May 10]. https://doi.org/10.1101/2020.05.06.20093476 [ Links ]
Euroimmun. Diagnóstico de Coronavirus: metodologia ELISA: Anti SARS-CoV-2 ELISA (IgA/IgG). São Caetano do Sul, SP: Euroimmun Brasil; 2019 [2021 Abr 1]. Available from: https://brasil.euroimmun.com.br/coronavirus [ Links ]
Kubina R, Dziedzic A. Molecular and serological tests for COVID-19. A comparative review of SARS-CoV-2 Coronavirus laboratory and point-of-care diagnostics. Diagnostics (Basel). 2020;10(6):434. https://doi.org/10.3390/diagnostics10060434 [ Links ]
Ministério da Saúde (BR), DATASUS. FormSus®-Versão 3.0. Brasília, DF: DATASUS; 2020 [cited 2020 Jun 10]. Available from: https://formsus.datasus.gov.br/site/default.php [ Links ]
Rosenberg ES, Tesoriero JM, Rosenthal EM, Chung R, Barranco MA, Styer LM, et al. Cumulative incidence and diagnosis of SARS-CoV-2 infection in New York. Ann Epidemiol. 2020;48:23-9.e4. https://doi.org/10.1016/j.annepidem.2020.06.00 [ Links ]
Pollán M, Pérez-Gómez B, Pastor-Barriuso R, Oteo J, Hernán MA, Pérez-Olmeda M, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet. 2020;396(10250):535-44. https://doi.org/10.1016/S0140-6736(20)31483-5 [ Links ]
Stringhini S, Wisniak A, Piumatti G, Azman AS, Lauer SA, Baysson H, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet. 2020;396(10247):313-9. https://doi.org/10.1016/S0140-6736(20)31304-0 [ Links ]
Ward H, Atchison C, Whitaker M, Ainslie KEC, Elliott J, Okell L, et al. Antibody prevalence for SARS-CoV-2 following the peak of the pandemic in England: REACT2 study in 100,000 adults. medRxiv [Preprint]. 2020 [posted 2020 Aug 21]. https://doi.org/10.1101/2020.08.12.20173690 [ Links ]
Liu A, Li Y, Wan Z, Wang W, Lei X, Lv Y. Seropositive prevalence of antibodies against SARS-CoV-2 in Wuhan, China. JAMA Netw Open. 2020;3(10):e2025717. https://doi.org/10.1001/jamanetworkopen.2020.25717 [ Links ]
Hallal PC, Hartwig FP, Horta BL, Silveira MF, Struchiner CJ, Vidaletti LP, et al. SARS-CoV-2 antibody prevalence in Brazil: results from two successive nationwide serological household surveys. Lancet Glob Health. 2020;8(11):e1390-8. https://doi.org/10.1016/S2214-109X(20)30387-9 [ Links ]
Tess BH, Granato CFH, Alves MCGP, Pintao MC, Rizzatti E, Nunes MC, et al. SARS-CoV-2 seroprevalence in the municipality of São Paulo, Brazil, ten weeks after the first reported case. medRxiv [Preprint]. 2020 [posted 2020 Jun 29]. https://doi.org/10.1101/2020.06.29.20142331 [ Links ]
Gomes CC, Cerutti Junior C, Zandonade E, Maciel ELN, Alencar FEC, Almada GL, et al. A population-based study of the prevalence of COVID-19 infection in Espírito Santo, Brazil: methodology and results of the first stage. medRxiv [Preprint]. 2020 [posted 2020 Jun 16]. https://doi.org/10.1101/2020.06.13.20130559 [ Links ]
Bermudi PMM, Lorenz C, Aguiar BS, Failla MA, Barrozo LV, Chiaravalloti-Neto F. Spatiotemporal ecological study of COVID-19 mortality in the city of São Paulo, Brazil: shifting of the high mortality risk from areas with the best to those with the worst socio-economic conditions. Travel Med Infect Dis. 2021;39:101945. https://doi.org/10.1016/j.tmaid.2020.101945 [ Links ]
Menezes AMB, Victora CG, Hartwig FP, Silveira MF, Horta BL, Barros AJD, et al. High prevalence of symptoms among Brazilian subjects with antibodies against SARS-CoV-2: a nationwide household survey. medRxiv [Preprint]. 2020 [posted 2020 Aug 12]. https://doi.org/10.1101/2020.08.10.20171942 [ Links ]
Naranbhai V, Chang CC, Beltran WFG, Miller TE, Astudillo MG, Villalba JA, et al. High seroprevalence of Anti-SARS-CoV-2 antibodies in Chelsea, Massachusetts. J Infect Dis. 2020;222(12):1955-9. https://doi.org/10.1093/infdis/jiaa579 [ Links ]
Silva AAM, Lima-Neto LG, Azevedo CMPS, Costa LMM, Bragança MLBM, Barros Filho AKD, et al. Population-based seroprevalence of SARS-CoV-2 and the herd immunity threshold in Maranhão. Rev Saude Publica. 2020;54:131. https://doi.org/10.11606/s1518-8787.2020054003278 [ Links ]
Lastrucci V, Lorini C, Del Riccio M, Gori E, Chiesi F, Sartor G, et al. SARS-CoV-2 seroprevalence survey in people involved in different essential activities during the general lock-down phase in the Province of Prato (Tuscany, Italy). Vaccines (Basel). 2020;8(4):778. https://doi.org/10.3390/vaccines8040778 [ Links ]
Chen Y, Tong X, Wang J, Huang W, Yin S, Huang R, et al. High SARS-CoV-2 antibody prevalence among healthcare workers exposed to COVID-19 patients. J Infect. 2020;81(3):420-6. https://doi.org/10.1016/j.jinf.2020.05.067 [ Links ]
Published
Issue
Section
License
Copyright (c) 2021 José Olimpio Moura de Albuquerque, Gabriela Akemi Kamioka
This work is licensed under a Creative Commons Attribution 4.0 International License.
